Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (2): 97-104.doi: 10.35541/cjd.20200802
• Guidelines and Consensus • Previous Articles Next Articles
Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China
Received:
2020-08-14
Revised:
2020-12-20
Online:
2021-02-15
Published:
2021-01-29
Contact:
Wang Baoxi
E-mail:wangbx@vip.126.com
Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement (2021 version)[J]. Chinese Journal of Dermatology, 2021, 54(2): 97-104.doi:10.35541/cjd.20200802
[1] | Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States[J]. J Am Acad Dermatol, 2013,68(3):412⁃419. doi: 10.1016/j.jaad.2012.07.027. |
[2] | Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem[J]. J Am Acad Dermatol, 2015,73(5 Suppl 1):S4⁃S7. doi: 10.1016/j.jaad.2015.07.052. |
[3] | Vinding GR, Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population⁃based study of possible hidradenitis suppurativa[J]. Br J Dermatol, 2014,170(4):884⁃889. doi: 10.1111/bjd.12787. |
[4] | Garg A, Kirby JS, Lavian J, et al. Sex⁃ and age⁃adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States[J]. JAMA Dermatol, 2017,153(8):760⁃764. doi: 10.1001/jamadermatol.2017.0201. |
[5] | Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment[J]. Clin Cosmet Investig Dermatol, 2017,10:105⁃115. doi: 10.2147/CCID.S111019. |
[6] | Lee JH, Kwon HS, Jung HM, et al. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population⁃based study[J]. J Eur Acad Dermatol Venereol, 2018,32(10):1784⁃1790. doi: 10.1111/jdv.15071. |
[7] | Yang JH, Moon J, Kye YC, et al. Demographic and clinical features of hidradenitis suppurativa in Korea[J]. J Dermatol, 2018,45(12):1389⁃1395. doi: 10.1111/1346⁃8138.14656. |
[8] | Kurokawa I, Hayashi N, Japan Acne Research Society. Questionnaire surveillance of hidradenitis suppurativa in Japan[J]. J Dermatol, 2015,42(7):747⁃749. doi: 10.1111/1346⁃8138. 12881. |
[9] | Wang B, Yang W, Wen W, et al. Gamma⁃secretase gene mutations in familial acne inversa[J]. Science, 2010,330(6007):1065. doi: 10.1126/science.1196284. |
[10] | Pink AE, Simpson MA, Desai N, et al. γ⁃Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis[J]. J Invest Dermatol, 2013,133(3):601⁃607. doi: 10.1038/jid. 2012.372. |
[11] | He Y, Xu H, Li C, et al. Nicastrin/miR⁃30a⁃3p/RAB31 axis regulates keratinocyte differentiation by impairing EGFR signaling in familial acne inversa[J]. J Invest Dermatol, 2019,139(1):124⁃134. doi: 10.1016/j.jid.2018.07.020. |
[12] | Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa[J]. Br J Dermatol, 2015,173(6):1431⁃1439. doi: 10. 1111/bjd.14075. |
[13] | Witte⁃Händel E, Wolk K, Tsaousi A, et al. The IL⁃1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction[J]. J Invest Dermatol, 2019,139(6):1294⁃1305. doi: 10.1016/j.jid.2018.11.018. |
[14] | Thomi R, Cazzaniga S, Seyed Jafari SM, et al. Association of hidradenitis suppurativa with T helper 1/T helper 17 phenotypes: a semantic map analysis[J]. JAMA Dermatol, 2018,154(5):592⁃595. doi: 10.1001/jamadermatol.2018.0141. |
[15] | Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa[J]. J Invest Dermatol, 2016,136(9):1768⁃1780. doi: 10.1016/j.jid.2016.04.036. |
[16] | Xu H, He Y, Hui Y, et al. NCSTN mutations in hidradenitis suppurativa/acne inversa do not influence cytokine production by peripheral blood mononuclear cells[J]. Br J Dermatol, 2017,176(1):277⁃279. doi: 10.1111/bjd.15076. |
[17] | Byrd AS, Carmona⁃Rivera C, O′Neil LJ, et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa[J]. Sci Transl Med, 2019,11(508):eaav5908. doi: 10.1126/scitranslmed.aav5908. |
[18] | Kanni T, Zenker O, Habel M, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?[J]. Br J Dermatol, 2018,179(2):413⁃419. doi: 10.1111/bjd.16428. |
[19] | Giamarellos⁃Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX⁃1 in hidradenitis suppurativa: an open⁃label single⁃arm trial in patients not eligible for adalimumab[J]. Br J Dermatol, 2020,183(1):176⁃178. doi: 10.1111/bjd.18877. |
[20] | Ring HC, Thorsen J, Saunte DM, et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls[J]. JAMA Dermatol, 2017,153(9):897⁃905. doi: 10.1001/jamadermatol.2017.0904. |
[21] | Ring HC, Bay L, Nilsson M, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa[J]. Br J Dermatol, 2017,176(4):993⁃1000. doi: 10.1111/bjd.15007. |
[22] | Ring HC, Emtestam L. The microbiology of hidradenitis suppurativa[J]. Dermatol Clin, 2016,34(1):29⁃35. doi: 10.1016/j.det.2015.08.010. |
[23] | Lyons AB, Shabeeb N, Nicholson CL, et al. Emerging medical treatments for hidradenitis suppurativa[J]. J Am Acad Dermatol, 2020,83(2):554⁃562. doi: 10.1016/j.jaad.2020.04.009. |
[24] | Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa[J]. Eur J Pharmacol, 2011,672(1⁃3):1⁃8. doi: 10.1016/j.ejphar.2011.08. 047. |
[25] | Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa?[J]. Exp Dermatol, 2008,17(5):455⁃472. doi: 10.1111/j.1600⁃0625.2008.00712_ 1.x. |
[26] | van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes[J]. J Am Acad Dermatol, 2015,73(5 Suppl 1):S23⁃S26. doi: 10.1016/j.jaad.2015.07.047. |
[27] | Lu L, Lai H, Pan Z, et al. Clinical and histopathological characteristics in patients with scarring folliculitis type of acne inversa[J]. Dermatoendocrinol, 2017,9(1):e1361575. doi: 10. 1080/19381980.2017.1361575. |
[28] | Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa[J]. J Eur Acad Dermatol Venereol, 2015,29(4):619⁃644. doi: 10.1111/jdv.12966. |
[29] | Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management[J]. J Am Acad Dermatol, 2019,81(1):76⁃90. doi: 10.1016/j.jaad.2019.02. 067. |
[30] | Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach[M]//Roenigh R, Roenigh H. Dermatologic Surgery. New York: Marcel Dekker, 1989:729⁃739. |
[31] | Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa[J]. Br J Dermatol, 2003,149(1):211⁃213. doi: 10.1046/j.1365⁃2133.2003.05390.x. |
[32] | Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity[J]. Br J Dermatol, 2009,161(4):831⁃839. doi: 10. 1111/j.1365⁃2133.2009.09198.x. |
[33] | Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa[J]. JAMA Dermatol, 2018,154(3):330⁃335. doi: 10.1001/jamadermatol.2017.5890. |
[34] | Amano M, Grant A, Kerdel FA. A prospective open⁃label clinical trial of adalimumab for the treatment of hidradenitis suppurativa[J]. Int J Dermatol, 2010,49(8):950⁃955. doi: 10. 1111/j.1365⁃4632.2010.04545.x. |
[35] | Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial[J]. J Am Acad Dermatol, 2010,62(2):205⁃217. doi: 10.1016/j.jaad. 2009.06.050. |
[36] | Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo⁃controlled portion of a phase 2 adalimumab study[J]. J Eur Acad Dermatol Venereol, 2016,30(6):989⁃994. doi: 10.1111/jdv.13216. |
[37] | Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity[J]. Br J Dermatol, 2017,177(5):1401⁃1409. doi: 10. 1111/bjd.15748. |
[38] | Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial[J]. Ann Intern Med, 2012,157(12):846⁃855. doi: 10.7326/0003⁃4819⁃157⁃12⁃201212180⁃00004. |
[39] | Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018[J]. Br J Dermatol, 2019,180(5):1009⁃1017. doi: 10.1111/bjd.17537. |
[40] | Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management[J]. J Am Acad Dermatol, 2019,81(1):91⁃101. doi: 10.1016/j.jaad.2019.02.068. |
[41] | Zouboulis CC, Bechara FG, Dickinson⁃Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization ⁃ systematic review and recommendations from the HS ALLIANCE working group[J]. J Eur Acad Dermatol Venereol, 2019,33(1):19⁃31. doi: 10.1111/jdv.15233. |
[42] | Gulliver W, Landells I, Morgan D, et al. Hidradenitis suppurativa: a novel model of care and an integrative strategy to adopt an orphan disease[J]. J Cutan Med Surg, 2018,22(1):71⁃77. doi: 10.1177/1203475417736290. |
[43] | Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document[J]. J Cutan Med Surg, 2017,21(6):513⁃524. doi: 10.1177/1203475417716117. |
[44] | Gulliver W, Zouboulis CC, Prens E, et al. Evidence⁃based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa[J]. Rev Endocr Metab Disord, 2016,17(3):343⁃351. doi: 10.1007/s11154⁃016⁃9328⁃5. |
[45] | Hunger RE, Laffitte E, Läuchli S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa[J]. Dermatology, 2017,233(2⁃3):113⁃119. doi: 10.1159/000477459. |
[46] | Magalhães RF, Rivitti⁃Machado MC, Duarte GV, et al. Consensus on the treatment of hidradenitis suppurativa ⁃ Brazilian Society of Dermatology[J]. An Bras Dermatol, 2019,94(2 Suppl 1):7⁃19. doi: 10.1590/abd1806⁃4841.20198607. |
[47] | Braunberger TL, Nartker NT, Nicholson CL, et al. Ertapenem ⁃ a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa[J]. Int J Dermatol, 2018,57(9):1088⁃1093. doi: 10.1111/ijd.14036. |
[48] | Maarouf M, Clark AK, Lee DE, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials[J]. J Dermatolog Treat, 2018,29(5):441⁃449. doi: 10.1080/09546634.2017.1395806. |
[49] | Miller I, Lynggaard CD, Lophaven S, et al. A double⁃blind placebo⁃controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa[J]. Br J Dermatol, 2011,165(2):391⁃398. doi: 10.1111/j.1365⁃2133.2011.10339.x. |
[50] | Poveda I, Vilarrasa E, Martorell A, et al. Serum zinc levels in hidradenitis suppurativa: a case⁃control study[J]. Am J Clin Dermatol, 2018,19(5):771⁃777. doi: 10.1007/s40257⁃018⁃0374⁃5. |
[51] | Hotz C, Sbidian E, Ingen⁃Housz⁃Oro S, et al. Thalidomide in severe hidradenitis suppurativa: a therapeutic option[J]. Acta Derm Venereol, 2019,99(12):1170⁃1171. doi: 10.2340/00015 555⁃3268. |
[52] | Iwasaki J, Marra DE, Fincher EF, et al. Treatment of hidradenitis suppurativa with a nonablative radiofrequency device[J]. Dermatol Surg, 2008,34(1):114⁃117. doi: 10.1111/j.1524⁃4725.2007.34025.x. |
[53] | Wilden S, Friis M, Tuettenberg A, et al. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)[J/OL]. J Dermatolog Treat, 2019:1⁃8(2019⁃10⁃17). doi: 10.1080/09546634.2019.1677842. https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1677842. |
[54] | Mahmoud BH, Tierney E, Hexsel CL, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long⁃pulsed neodymium:yttrium⁃aluminium⁃garnet laser[J]. J Am Acad Dermatol, 2010,62(4):637⁃645. doi: 10.1016/j.jaad.2009.07.048. |
[55] | Mordon S. Treating hidradenitis suppurativa with photodynamic therapy[J]. J Cosmet Laser Ther, 2018,20(4):223⁃228. doi: 10. 1080/14764172.2017.1400169. |
[56] | Emtestam L, Lapins J, Sartorius K. Carbon dioxide laser treatment using methylene blue⁃assisted sinus tract identification in hidradenitis suppurativa[J]. Dermatol Surg, 2017,43(4):604⁃605. doi: 10.1097/DSS.0000000000001068. |
[57] | Vekic DA, Cains GD. Hidradenitis suppurativa ⁃ management, comorbidities and monitoring[J]. Aust Fam Physician, 2017,46(8):584⁃588. |
[1] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
[2] | Li Suo, Xiang Ruiyu, Li Zhiliang, Jing Ke, Wang Yuan, Zhang Hanmei, Feng Suying. Evaluation of the value of indirect immunofluorescence on salt-split skin in the diagnosis of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2022, 55(3): 235-237. |
[3] | Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279. |
[4] | Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212. |
[5] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022) [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
[6] | Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694. |
[7] | Jiao Xiaoyan, Yin Guangwen, Yin Yakun, Li Dongqin. Clinical analysis of 25 cases of herpes zoster during pregnancy or the perinatal period [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210384-e20210384. |
[8] | Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631. |
[9] | Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184. |
[10] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
[11] | Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64. |
[12] | Cheng Bihong, Dou Xia. Diagnosis and classification of chronic prurigo [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210130-e20210130. |
[13] | Luan Chao, Hu Yu, Chen Kun, Zhang Jiaan, Gu Heng, Zhang Ronglin, Zhang Xiaohua, Tian Panpan, Zhu Yan, Zhuang Chen, Huang Dan, Ju Mei. Efficacy and safety of 308-nm SQ light-emitting diode light and 308-nm excimer light in the treatment of facial vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(1): 16-19. |
[14] | Wang Yuan, Yu Meiwen, Xiang Ruiyu, Li Suo, Li Zhiliang, Jin Ke, Zhang Hanmei, Feng Suying. Optimization of indirect immunofluorescence on salt-split skin and its application in detection of bullous pemphigoid antibodies [J]. Chinese Journal of Dermatology, 2022, 55(1): 12-15. |
[15] | Zhang Ying, Gan Lu, Li Siqi, Li Yan, Song Hao, Shao Xuebao, Zhang Wei, Xu Xiulian, Jiang Yiqun, Zeng Xuesi, Chen Hao, Sun Jianfang. Clinicopathological and immunophenotypic analysis of 24 cases of transformed mycosis fungoides [J]. Chinese Journal of Dermatology, 2022, 55(1): 20-26. |
|